The recent surge in Quest Diagnostics (DGX) shares has intrigued many. Ranked as a robust value stock, it has exhibited consistent growth. In 2024, Quest Diagnostics produced strong revenues alongside revealing a promising growth strategy for the coming years. The major healthcare diagnostic provider is set to declare its Q2 2025 results, having released its Corporate Responsibility Reports and a multitude of new diagnostic services.
Quest Diagnostics has been expanding healthcare access with remarkable steps like allocating $13M in grants, distributing a million free tests, and offering 50 new diagnostic services. The company completed the acquisition of the Outreach Lab Services Business of University Hospitals and LifeLabs, which increased access to diagnostic innovation. Further, it has entered a development deal with MD Anderson for a multi-cancer stratification (MCaST) blood test.
The company’s performance has been rewarded by Wall Street, with stock outperforming both the Nasdaq and the S&P 500. Value investors regard Quest Diagnostics as a significant opportunity in the long-term. Moreover, the business reports solid dividends, and its innovative blood test holds the potential to transform early cancer detection.
The future trajectory of Quest Diagnostics looks promising, marked by continued revenue growth and dedication to healthcare innovation.Quest Diagnostics DGX News Analytics from Mon, 26 Aug 2024 07:00:00 GMT to Sat, 28 Jun 2025 06:15:03 GMT - Rating 9 - Innovation 6 - Rumor 6
